GBI Secures Commercial Manufacturing Contract, Solidifying Leadership in Radiopharmaceutical Manufacturing
Experience.
History-Making.
Goodwin Biotechnology Inc. (GBI) Announces First Commercial Contract Signing
Goodwin Biotechnology Inc. is now GBI, as Part of their Rebranding Initiative on their 30-Year Anniversary!
Goodwin Biotechnology Announces the Appointment of Darrin T. Schellin as Chief Executive Officer
AST and Goodwin Biotechnology Partner on a GENiSYS® C20 Aseptic Small Batch Filling & Closing Machine
Goodwin Biotechnology Launches a Digitization Initiative by Investing in a Sophisticated Electronic Quality Solution
Goodwin Biotechnology Announces the Appointment of Kent Payne, Ph.D. and Brandon Price, Ph.D. to its Board of Directors
Goodwin Biotechnology Secures Significant Institutional Investment in New Round of Growth Capital Financing
Radimmune Therapeutics Selected Goodwin Biotechnology for Process Development through cGMP Manufacturing of their IgG Monoclonal Antibody and Conjugate
